File downloaded on 2026-11-28
Source URL: https://medicines.health.europa.eu/veterinary/en/600000002502

Innovax-ND-IBD (--) - Suspension and solvent for suspension for injection

Authorised

- Turkey herpesvirus, strain HVP360 (cell-associated), encoding fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus, Live

Product identification

Medicine name:
Innovax-ND-IBD (--) - Suspension and solvent for suspension for injection

Active substance:
Turkey herpesvirus, strain HVP360 (cell-associated), encoding fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus, Live

Target species:
Chicken
Chicken (embryonated eggs)

Route of administration:
In ovo
Subcutaneous use

Product details

Active substance and strength:
Turkey herpesvirus, strain HVP360 (cell-associated), encoding fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus, Live
Presentation_strength:$10^{3,3}$-$10^{4,6}$ PFU Reference:Hse Index:0

Pharmaceutical form:
Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:
In ovo:

- **Chicken**
  - Not applicable. 0 day Zero days
- **Chicken (embryonated eggs)**
  - Not applicable. 0 day Zero days

Subcutaneous use:

- **Chicken**
  - Not applicable. 0 day Zero days
- **Chicken (embryonated eggs)**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AD16

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Bulgaria , Cyprus , Czechia , Denmark , France , Germany , Greece , Hungary , Ireland , Italy , Netherlands , Poland , Portugal , Romania , Spain , United Kingdom (Northern Ireland)

Package description:

Packaging:Concentrate: ampoule (glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 2 ml (4000 doses)

Packaging:Concentrate: ampoule (glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 2 ml (2000 doses)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:

22/08/2017

Manufacturing sites for batch release:

Intervet International B.V.

Responsible authority:

European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
22/08/2017

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 14/03/2026
Download

ema-puar-v4422-innovax-nd-ibd-ii-0004-en.pdf

ema-puar-innovax-nd-ibd-v-4422-par-en.pdf